회사 개요
Chemed Corporation operates as a leading provider of hospice and palliative care services, delivering comprehensive end-of-life support through a specialized network that includes physicians, registered nurses, home health aides, social workers, and clergy members primarily within the United States. This business model places the company firmly within the Healthcare sector, specifically the Medical Care Facilities industry, where it addresses critical patient needs by managing complex medical care and comfort for terminally ill individuals. The enterprise demonstrates significant scale with a total market capitalization of $5.71 billion and an annual revenue stream of $2.53 billion, supported by a workforce of 15,811 employees dedicated to patient care operations. These substantial valuation and revenue figures indicate that Chemed holds a considerable position within its niche, reflecting strong market confidence and a robust operational footprint that supports its status as a major player in the palliative care landscape.
재무 건전성
The company reported a trailing twelve-month revenue of $2.53 billion, generating net income of $265.24 million and an EBITDA of $404.40 million, which highlights a specific cost structure where non-interest expenses and taxes consume a significant portion of top-line earnings. The gap between the $2.53 billion revenue and the $265.24 million net income reveals that the company's operating costs, including the substantial labor force and overhead associated with care delivery, result in a net profit margin of 10.5%. Free cash flow stands at $246.01 million, indicating that after capital expenditures, the company retains sufficient liquidity to fund operations, service debt, or return capital without needing to raise external financing immediately. The gross margin is reported at 32.5%, suggesting that the company retains over a third of its revenue after direct costs, while the operating margin of 16.6% reflects the efficiency of its broader administrative and operational functions. However, the profit margin of 10.5% indicates that after all expenses including interest and taxes, the final profitability is more compressed than the operating efficiency might initially suggest. On the balance sheet, cash holdings of $74.52 million are significantly lower than total debt of $143.76 million, and the debt-to-equity ratio of 14.68 suggests a highly leveraged capital structure rather than a conservative stance. Despite the high leverage, the current ratio of 1.05 indicates that the company possesses sufficient current assets to cover its current liabilities, maintaining a baseline of short-term liquidity. Return on equity is calculated at 25.3% and return on assets at 13.4%, metrics that reveal management is effectively utilizing shareholder capital and company assets to generate returns, particularly notable given the high debt levels and the asset-heavy nature of the healthcare services industry.
밸류에이션 평가
The trailing twelve-month P/E ratio is 21.32, while the forward P/E is projected at 14.68, implying that the market expects a significant multiple contraction or that current earnings are elevated relative to future expectations. The price-to-book ratio stands at 5.47, indicating that the stock trades at a substantial premium to its book value, which is common for companies with strong intangible assets or high-return service models like hospice care. Alternative valuation metrics such as the price-to-sales ratio of 2.26 and the EV/EBITDA of 13.47 provide additional context, suggesting the market values the company's sales and earnings generation at levels that reflect its growth potential and stability despite current earnings declines. The 52-week trading range spans from a low of $365.21 to a high of $604.91, providing a clear view of the stock's volatility and recent price discovery within this wide band. The beta of 0.48 indicates that the stock exhibits low price volatility relative to the broader market, moving less than half as much as the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is recorded at -0.1%, while earnings growth is declining at -9.1%, demonstrating that earnings are shrinking at a much faster rate than revenue, which implies a potential compression in margins or a one-time impact on profitability not yet reflected in the top line. The company currently offers a dividend yield of 0.6% with a payout ratio of 12.0%, a low payout level that suggests the company retains most of its earnings rather than distributing them, which is a prudent approach given the negative earnings growth trajectory. With such a low payout ratio, the company maintains significant flexibility to reinvest earnings into operational improvements or to sustain dividends even if future earnings decline further, though the current negative earnings growth makes the sustainability of any higher dividend levels a concern. The overall growth and income profile presents a mixed picture of stable but slightly declining earnings and a minimal dividend yield, characteristic of a mature service business facing headwinds in its specific healthcare segment.